stockrowKymera Therapeutics, Inc.
KYMR Healthcare Biotechnology
Kymera Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $39.2 million, down 16.7% from fiscal 2024.
- Revenue
- +466.4%
- EPS
- −40.3%
- Free cash flow
- −186.6%
- Total debt
- −66.6%
Quarter to September 2026, against a year earlier
Follow KYMR
Alert me
Kymera Therapeutics, Inc. (KYMR) Return on invested capital
Kymera Therapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −39.3%, down 9.5 percentage points from fiscal 2025 (−29.8%). Over the past ten years it has ranged from −483.6% (fiscal 2023) to 0.00% (fiscal 2020); the current reading is higher than 63% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −29.8% | 17.04 |
| FY2024 | −46.8% | 436.80 |
| FY2023 | −483.6% | (363.99) |
| FY2022 | −119.7% | 222.57 |
| FY2021 | −342.2% | (342.22) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| CAI Caris Life Sciences,�Inc. compare | 22.2% |
| TGTX TG Therapeutics, Inc. compare | 10.7% |
| TECH Bio-Techne Corp compare | 7.70% |
| BMRN BioMarin Pharmaceutical Inc. compare | 0.73% |
| SMMT Summit Therapeutics PLC compare | 0.00% |
| IBRX ImmunityBio, Inc. compare | 0.00% |
| TWST Twist Bioscience Corporation compare | −30.8% |
| KYMR Kymera Therapeutics, Inc. | −39.3% |
| PCVX Vaxcyte, Inc. compare | −57.3% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on KYMR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement